Treatment Recommendations for Stage 3 Non-Small Cell Lung Cancer
Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins, Medicine, discusses the change in standard of care for patients with stage 3 non-small cell lung cancer (NSCLC). Durvalumab (Imfinzi) has been approved by the FDA as a consolidation therapy.
This approval came based on data from the PACIFIC trial, which found a significant advantage in control of disease as well as progression-free survival, Brahmer says. She added that this trial compared the addition of durvalumab to a placebo after concurrent chemotherapy and radiation. Investigators did not find an increase in overall toxicity with the addition of durvalumab.
Brahmer hopes they will have the overall survival data soon from this trial, but as of now, the addition of durvalumab after concurrent chemotherapy and radiation is the new standard of care for patients with unresectable stage 3 disease. Durvalumab has shown to improve survival of these patients.
For more resources and information regarding anticancer targeted therapies in lung cancer: http://www.targetedonc.com/resource-center/lung
-
Category
No comments found